The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Castrate Resistant Prostate Cancer Therapeutics Market Research Report 2025
Synopsis
Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.
The treatment of castration-resistant prostate cancer is to use various methods to treat the recurrence and metastasis of cancer cells or to control hormones.
The global Castrate Resistant Prostate Cancer Therapeutics market was valued at US$ 15180 million in 2023 and is anticipated to reach US$ 32320 million by 2030, witnessing a CAGR of 11.2% during the forecast period 2024-2030.
Global key players of castrate resistant prostate cancer therapeutics include Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Jiangsu Hengrui Pharmaceuticals etc. The top five players hold a share over 70%. North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.
This report aims to provide a comprehensive presentation of the global market for Castrate Resistant Prostate Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castrate Resistant Prostate Cancer Therapeutics.
Report Scope
The Castrate Resistant Prostate Cancer Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Castrate Resistant Prostate Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castrate Resistant Prostate Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
Segment by Type
Hormonal Therapy
Chemotherapy
Others
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castrate Resistant Prostate Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.
The treatment of castration-resistant prostate cancer is to use various methods to treat the recurrence and metastasis of cancer cells or to control hormones.
The global Castrate Resistant Prostate Cancer Therapeutics market was valued at US$ 15180 million in 2023 and is anticipated to reach US$ 32320 million by 2030, witnessing a CAGR of 11.2% during the forecast period 2024-2030.
Global key players of castrate resistant prostate cancer therapeutics include Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Jiangsu Hengrui Pharmaceuticals etc. The top five players hold a share over 70%. North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.
This report aims to provide a comprehensive presentation of the global market for Castrate Resistant Prostate Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castrate Resistant Prostate Cancer Therapeutics.
Report Scope
The Castrate Resistant Prostate Cancer Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Castrate Resistant Prostate Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castrate Resistant Prostate Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
Segment by Type
Hormonal Therapy
Chemotherapy
Others
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castrate Resistant Prostate Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Hormonal Therapy
1.2.3 Chemotherapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Perspective (2019-2030)
2.2 Castrate Resistant Prostate Cancer Therapeutics Growth Trends by Region
2.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Castrate Resistant Prostate Cancer Therapeutics Market Dynamics
2.3.1 Castrate Resistant Prostate Cancer Therapeutics Industry Trends
2.3.2 Castrate Resistant Prostate Cancer Therapeutics Market Drivers
2.3.3 Castrate Resistant Prostate Cancer Therapeutics Market Challenges
2.3.4 Castrate Resistant Prostate Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue
3.1.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Castrate Resistant Prostate Cancer Therapeutics Revenue
3.4 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2023
3.5 Castrate Resistant Prostate Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Castrate Resistant Prostate Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Castrate Resistant Prostate Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Type
4.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2025-2030)
5 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Application
5.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size (2019-2030)
6.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2019-2024)
6.4 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size (2019-2030)
7.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2019-2024)
7.4 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size (2019-2030)
9.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer/Astellas (Xtandi)
11.1.1 Pfizer/Astellas (Xtandi) Company Detail
11.1.2 Pfizer/Astellas (Xtandi) Business Overview
11.1.3 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Introduction
11.1.4 Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.1.5 Pfizer/Astellas (Xtandi) Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Introduction
11.2.4 Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 AstraZeneca/Merck (Lynparza)
11.3.1 AstraZeneca/Merck (Lynparza) Company Detail
11.3.2 AstraZeneca/Merck (Lynparza) Business Overview
11.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Introduction
11.3.4 AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.3.5 AstraZeneca/Merck (Lynparza) Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Introduction
11.4.4 Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 Jiangsu Hengrui Pharmaceuticals
11.5.1 Jiangsu Hengrui Pharmaceuticals Company Detail
11.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Introduction
11.5.4 Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.5.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.6 CTTQ
11.6.1 CTTQ Company Detail
11.6.2 CTTQ Business Overview
11.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Introduction
11.6.4 CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.6.5 CTTQ Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Introduction
11.7.4 Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.7.5 Sanofi Recent Development
11.8 Hansoh
11.8.1 Hansoh Company Detail
11.8.2 Hansoh Business Overview
11.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Introduction
11.8.4 Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.8.5 Hansoh Recent Development
11.9 Clovis Oncology
11.9.1 Clovis Oncology Company Detail
11.9.2 Clovis Oncology Business Overview
11.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Introduction
11.9.4 Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.9.5 Clovis Oncology Recent Development
11.10 Zhendong Pharmaceutical
11.10.1 Zhendong Pharmaceutical Company Detail
11.10.2 Zhendong Pharmaceutical Business Overview
11.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Introduction
11.10.4 Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2024)
11.10.5 Zhendong Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
